First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Published:2016-05-25 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Greenhalgh Janette¹,Dwan Kerry²,Boland Angela¹,Bates Victoria¹,Vecchio Fabio¹,Dundar Yenal¹,Jain Pooja³,Green John A⁴

Affiliation:

1. University of Liverpool; Liverpool Reviews and Implementation Group; Sherrington Building Ashton Street Liverpool UK L69 3GE

2. Cochrane Central Executive; St Albans House, 57-59 Haymarket London England UK SW1Y 4QX

3. Clatterbridge Cancer Centre; Clatterbridge Road Bebington Merseyside UK CH63 4JY

4. University of Liverpool; Institute of Translational Medicine; Clatterbridge Cancer Centre Clatterbridge Road Bebington Merseyside UK CH63 4JY

Publisher

Wiley

Subject

Pharmacology (medical)

Reference135 articles.

1. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer;Khambata-Ford;Journal of Clinical Oncology,2010

2. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;Journal of Clinical Oncology,2010

3. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older;Chen;Journal of Thoracic Oncology,2012

4. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Annals of Oncology,2015

5. Quality of life (QOL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin in Asian patients with epidermal growth factor receptor (EGFR) mutation positive (MUT+) non-small cell lung cancer (NSCLC);Wu;Journal of Thoracic Oncology,2014

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supplementation with Fish Oil and Selenium Protects Lipolytic and Thermogenic Depletion of Adipose in Cachectic Mice Treated with an EGFR Inhibitor;Cells;2024-09-04

2. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status;BMC Pulmonary Medicine;2024-08-24

3. Therapeutic Effect of Resveratrol and its Novel Formulations on Lung Cancer: Focus on Biological Aspects and Underlying Pathways;Current Medicinal Chemistry;2024-08

4. Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients;Thoracic Cancer;2024-07-24

5. Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals;Expert Review of Anticancer Therapy;2024-07-08